Vol. 2 No. 11 (2022)
Reimbursement Reviews

Asciminib (Scemblix)

Published November 25, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses asciminib (Scemblix), 80 mg q.d. or 40 mg b.i.d. oral tablets.
  • Indication: For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase previously treated with 2 or more tyrosine kinase inhibitors.